The HIC Market and Who Actually Buys It

Hydrophobic interaction chromatography separates proteins by the strength of their hydrophobic patches, using a salt gradient that runs from high to low. Load a sample in a high concentration of a kosmotropic salt such as ammonium sulfate, and the protein sticks to a mildly hydrophobic ligand (butyl, phenyl, octyl, ether). Lower the salt, and molecules let go in order of hydrophobicity. Because the conditions are gentle, proteins keep their shape. That single property is why a technique with no flashy marketing is quietly written into most antibody and antibody-drug conjugate (ADC) control strategies.

So the first question for your plan is not "how big is chromatography." It is "which customer has a HIC problem that costs them money this quarter." There are three, and they pay in very different ways.

• ADC developers need drug-load data. HIC is the method of choice for drug-to-antibody ratio (DAR) and drug-load distribution on cysteine-linked ADCs, because it separates species carrying zero, two, four, six and eight payloads without denaturing the molecule (American Pharmaceutical Review). Every ADC lot needs it, repeatedly.
• Downstream process teams need a polishing step. HIC removes aggregates and product variants that ion-exchange leaves behind, and it sits in the purification train of many monoclonal antibody and biosimilar processes. These customers buy method development, resin screening and scale-up studies.
• Labs and manufacturers need consumables. Resins, pre-packed columns and analytical columns are bought on a repeat cycle. This is the lowest-margin and most predictable stream, and it is dominated by firms with decades of brand equity.

Market size: pick your number and say why

Published HIC market estimates disagree by a factor of two, and a lender who has read two of them will notice if your plan quotes only the largest. Allied Market Research projects the hydrophobic interaction chromatography market at $952.9 million globally by 2033, growing at a 7.5% CAGR (Allied Market Research via GlobeNewswire, 2025). Other publishers value the 2025 market anywhere from roughly $430 million to $920 million, with CAGRs between 7.0% and 8.7% (ResearchAndMarkets listing; Data Bridge). The resin segment alone is valued near $299 million in 2025 and a 6.1% CAGR to 2034 (Global Market Statistics).

The practical reading: the defensible market for a new entrant is not $950 million. It is the slice of ADC, biosimilar and cell-line-development work within a two-hour drive (or one-day courier) of your lab. A regional biotech cluster with 60 to 120 antibody and ADC programmes can easily consume 5,000 to 12,000 HIC injections a year. That is the number your revenue forecast should be built on, and the global figure belongs in one sentence in the industry overview.

Where the demand physically sits

Chromatography services follow molecules, and molecules follow venture money. In the United States, the dense clusters are Boston and Cambridge, Massachusetts, the Research Triangle in North Carolina, the San Francisco Bay Area and San Diego, and central New Jersey. In the UK the equivalents are the Cambridge and Stevenage corridor, the Oxford and Harwell campus, and Alderley Park in Cheshire. A lab in a metro with fewer than 30 antibody developers will spend its first two years shipping samples by courier, which is possible but should be priced into turnaround promises.

Market structure matters too. At the top of the pyramid sit global contract testing groups such as Eurofins BioPharma Product Testing, Intertek Pharmaceutical Services, Charles River Laboratories and SGS, plus ADC-specialist contract developers such as Abzena in the UK. They win large programmes under master service agreements. Your opening is the customer those firms treat as too small: a 12-person biotech with one ADC candidate that wants a three-day turnaround and a scientist on the phone, not a quote cycle.

Funding a Lab: What SBA and UK Lenders Will Underwrite

A HIC business is an equipment-heavy, qualified-staff business, which lenders understand better than a software start-up but still price carefully. The SBA 7(a) programme is the main US route and the facts below are worth putting in your plan so the reader sees you have checked them.

Two further points. The SBA's own programme page confirms 7(a) as its flagship general-purpose loan, and lenders set their own underwriting on top of it (SBA, 7(a) loans). Second, a lender will want to know what the collateral is. Analytical instruments are specialised, resell at a steep discount, and depreciate fast, so most lenders treat the equipment as weak security. Expect a personal guarantee, a lien on business assets, and an ask for 10% to 20% equity injection. Founders who hold a signed master service agreement or a letter of intent from even one named customer improve their odds far more than a longer forecast does.

The UK picture is different. The Start Up Loans scheme tops out at £25,000 per founder, which buys one column library and a cold room, not a laboratory. Realistic UK routes are an asset-finance lease on the HPLC (with the instrument vendor's own finance arm often cheapest), a bank term loan under the Recovery Loan or British Business Bank guarantee framework, Innovate UK grants where your method development work is genuinely novel, and SEIS or EIS for equity from angels if you are a company with a growth story. Our bespoke business plan service builds the lender and SEIS versions of the financials from one model.

If you are running a resin or column business instead of a lab, the funding profile flips. You need inventory and working capital rather than instruments, and receivables stretch to 45 to 60 days with large pharma buyers. A revolving line of credit or invoice finance matters more than a term loan.

What a HIC Business Costs to Open

The honest range for a one-system, 2,500 square foot analytical and method development lab is $380,000 to $1.1 million (£300K to £870K). The low end assumes refurbished instruments and a lease on existing wet-lab or flex space. The high end assumes a new bio-inert UHPLC, a preparative system for process work, and a full fit-out with fume extraction and purified water. A resin and pre-packed column business is a different shape: less equipment, but $250K to $700K of inventory and packing capability before first sales.

Working capital is the line that closes labs

Lab services bill after the work, and large customers pay on 45 to 60 day terms. A lab that books $35,000 a month of revenue is carrying $60,000 to $70,000 of receivables at any moment, before it has paid rent, two analysts and a courier. Budget at least six months of fixed costs as cash on day one. In the sample plan below, that is roughly $225,000, and it is the reason the funding ask is $410,000 rather than the $180,000 the equipment alone would suggest.

The second hidden line is time. A new HIC method for a specific ADC is not billable until it is developed, and a method that must survive a regulatory submission needs validation under ICH Q2(R2). Plan for 6 to 10 weeks from signed agreement to first reportable result on a new customer's molecule, and show that lag in your cash-flow model, not just in your sales pitch.

The Instrument and Consumables Bench List

Buyers sort HIC providers by what is on the bench. A plan that names real columns and real resins reads as credible in a way that "state-of-the-art equipment" never does. These are the products a competent HIC lab or resin reseller will actually stock, with the list prices we could verify.

Analytical HIC columns

Process-scale resins for screening work

The price pattern is the commercial insight. Cytiva's Capto Butyl ImpRes costs roughly $5,066 per litre against about $4,062 per litre for the older Butyl Sepharose High Performance, which tells you the premium that a higher-resolution, better-characterised resin commands. If you plan a reseller or pre-packed column line, you are buying at these list prices less a distributor discount and selling into customers who can order direct. That compresses your margin to 15% to 30% unless you add value in the form of packing, qualification data or a bundled screening service.

Capital equipment and software

• Bio-inert UHPLC. Salt gradients up to 2 M ammonium sulfate corrode stainless steel flow paths, so a metal-free or bio-inert system such as an Agilent 1290 Infinity II Bio is the standard purchase. Refurbished systems of this class list from roughly $20K to $60K on secondary markets; new configurations run well above that.
• Preparative or low-pressure system. A Cytiva ÄKTA-class workstation for process-scale scouting, typically $55K to $95K in our planning estimate. Skip it in year one if your plan is analytical-first.
• Chromatography data system. Waters Empower, Thermo Chromeleon or Agilent OpenLab. A part 11 compliant CDS with audit trails is a purchase requirement for GMP customers, not an upgrade.
• LIMS and eQMS. LabWare or STARLIMS for sample tracking; MasterControl or a comparable eQMS for SOPs, deviations and CAPA. Several of these are priced per user per year.
• Native HIC-MS (phase two). Online native HIC coupled to mass spectrometry is now documented for ADC characterisation and uses MS-friendly salts such as ammonium tartrate in place of ammonium sulfate (LCGC; mAbs, 2024). A high-resolution MS adds $300K to $600K, so lease access or subcontract until you have 10 repeat customers asking for it.
• Water, salts and solvents. Ultrapure water system, ammonium sulfate, sodium phosphate buffers, and isopropanol for the organic modifier many ADC methods add. Plan a licensed solvent waste contractor from day one.

Revenue Lines and Per-Injection Economics

The three business models below have the same chemistry and almost nothing else in common. Choose one as your spine and treat the others as year-three extensions, because lenders discount plans that try to be a lab, a manufacturer and a distributor at once.

A worked example: what one billed injection earns

Here is the arithmetic for the lab model, using a composite of our client work. All prices are planning estimates; test them against quotes from three named competitors before you publish your own.

• Price. A single HIC-HPLC DAR run with a one-page report: $240 average, within a $210 to $340 band by customer volume and turnaround.
• Column wear. A $1,753 column amortised over an assumed 900 injections is about $1.95 per run. Real life varies with sample cleanliness and salt handling.
• Salts, solvents and vials. About $1.60.
• Second-person data review. About $12, because GMP-adjacent customers expect a reviewer to sign off.
• Variable cost. Roughly $9 after rounding, leaving about $231 of contribution before staff, rent and equipment.

That contribution is high because labour is treated as fixed. It is the correct way to model a lab with a small team, and it is also why break-even is a utilisation question. One instrument running a 40 minute cycle (30 minute gradient plus re-equilibration) can complete about 18 injections in a working day, or around 3,960 in a 220 day year. A fixed-cost base of $450,000, offset by about $42,000 of margin from method development projects, breaks even at roughly 1,770 billed injections. That is 45% utilisation of one system, which is why our sample plan shows break-even in month 15 rather than month 6.

Project revenue stacks on top

• HIC method development and robustness. Screening salt type, starting concentration, gradient slope, pH and isopropanol percentage, usually through a design-of-experiments matrix. $9,000 to $22,000 per project.
• Resin screening and scale-up. 96-well or mini-column screening across Capto, Toyopearl and Sepharose chemistries, then bench-scale column runs to confirm dynamic binding capacity. $18,000 to $55,000 per project.
• Stability and comparability testing. A time-point schedule across 3, 6, 9 and 12 months creates recurring work that fills instrument time predictably, a revenue type lenders like.
• Retainers. A monthly block of 40 injections at a 10% discount smooths the cash cycle and is easier for a customer's procurement team to approve than a new purchase order each time.

Our market research and content package includes a competitor price sheet for your chosen region so these numbers rest on local quotes rather than our averages.

Compliance: FDA, MHRA and the EU

There is no single HIC licence. What you need depends on whether you test material that will be given to people. Research-use-only work for academic and discovery customers needs ordinary business registration, health and safety, and waste compliance. The moment a customer sends a clinical or commercial lot for release or stability testing, you are inside pharmaceutical GMP.

United States

• 21 CFR Part 211, Subpart I (laboratory controls). Contract testing laboratories are subject to 21 CFR parts 210 and 211, and section 211.160 requires scientifically sound specifications, sampling plans and test procedures (eCFR 21 CFR 211.160; FDA Q&A on laboratory controls).
• Establishment registration. Facilities performing testing for drug manufacturers typically register and list with FDA under section 510 of the FD&C Act. Confirm your exact obligation with a regulatory attorney before signing a GMP customer.
• Method and instrument qualification. USP chapter <621> governs chromatography system suitability; ICH Q2(R2) covers validation of analytical procedures. Instrument IQ/OQ/PQ is a one-off cost of $25K to $60K together with accreditation.
• State and local. Business licence, EIN, certificate of occupancy for a lab, fire department sign-off for flammable solvents, and a hazardous waste generator ID.
• Data integrity. FDA expects complete, attributable and time-stamped chromatography records. Your CDS must lock methods and keep audit trails.

United Kingdom

• MHRA GMP certificate. A standalone contract laboratory does not need a manufacturer's licence, but the MHRA issues a GMP certificate after inspection, and customers will ask for it (MHRA GMP inspection records). If you also handle or release clinical trial material you may need a MIA(IMP) licence.
• UKAS accreditation to ISO/IEC 17025. UKAS is the sole national accreditation body recognised by the UK government. Accreditation is not mandatory for GMP work but is a strong trust signal, and it costs time as much as money, often 9 to 12 months for a first assessment (UKAS laboratory publications).
• Health and safety. COSHH assessments for solvents and salts, and a competent person for waste.
• Company formation. Limited company at Companies House; if you want SEIS or EIS for equity investors, take advance assurance from HMRC before the round.

European Union

EU member states generally treat contract quality-control testing as a regulated manufacturing activity under Directive 2001/83/EC, so a testing site normally holds a manufacturing authorisation from its national competent authority. In Germany that is granted by the regional authority under section 13 of the Arzneimittelgesetz. EU GMP Chapter 7 (outsourced activities) and Annex 11 (computerised systems) set the quality-agreement and data rules your customers will audit against. If you plan to serve both sides of the Atlantic from one site, ask a customer's quality unit which certificate they will accept first. A UK lab serving EU sponsors faces the extra wrinkle that batch testing for the EU market typically has to be done in the EU or a mutual-recognition country.

Winning Your First Ten Customers

HIC is bought by a small number of people with unusual job titles: the head of analytical development, a CMC lead, a downstream process manager, or a quality director. They do not respond to display ads. They respond to a published application note, a conference poster and a colleague's recommendation. Your plan should name the four or five channels you will actually run and put a cost beside each.

• Application notes. Publish two or three of your own data sets, for example a DAR distribution on a commercially available antibody-drug conjugate reference or a variant separation on a NIST monoclonal antibody standard. Vendors such as Agilent publish exactly this kind of note, and a lab that does the same signals technical depth for the cost of a few days of instrument time.
• Conferences and local clusters. BIO International, the ADC-focused meetings in Boston and London, and regional BioNetwork events. Budget $8,000 to $20,000 a year in travel and registration, and measure it in qualified supplier-questionnaire requests, not business cards.
• Supplier-qualification packs. A tidy pack with your quality manual, an org chart, equipment list, a sample quality agreement and two redacted reports shortens the first call from forty minutes to ten.
• Partnerships with resin vendors. Cytiva, Tosoh and Merck all run application teams that field requests they cannot staff. Offering contract screening capacity on a referral basis costs nothing until it works.
• Direct LinkedIn and email outreach. A list of 300 antibody and ADC programmes within courier distance, built from clinical-trial registries and company pipelines, is a better asset than a website with a contact form.

Expect a sales cycle of 3 to 6 months for a first project and 6 to 9 months for a customer that will send GMP lots. Your first ten customers will probably come from three places: a former employer or collaborator, a referral from a vendor application scientist, and a conference conversation that turned into a pilot study. Build your plan around those three and treat anything else as upside.

A 12-month launch timeline

• Months 1 to 2. Form the company, sign the lease, order the UHPLC, and file for the business licence and hazardous waste ID. Sign your first quality-system consultant.
• Months 3 to 4. Install and qualify the instrument (IQ/OQ), validate the CDS, write the first 20 SOPs, and run your own application-note data sets.
• Months 5 to 6. Launch the website and supplier-qualification pack, attend the first conference, and close the pilot customer who signed the letter of intent.
• Months 7 to 9. Deliver the first paid method development project, record turnaround data, and start the accreditation application if you are in the UK.
• Months 10 to 12. Convert the pilot to a master service agreement, hire the third analyst only if utilisation has passed 35%, and update the forecast with real numbers for the lender's annual review.

If you want this timeline built into a Gantt chart and a monthly cash forecast that a lender can audit, the bespoke plan includes both as standard.

Mistakes That Sink HIC Start-Ups

Most failed chromatography ventures die of one of five avoidable problems. Put your mitigation for each in the risk section of your plan.

• Buying a stainless-steel instrument for a salt method. High-molarity ammonium sulfate attacks metal flow paths and leaves you with ghost peaks and an expensive repair. Specify bio-inert from the first quote.
• Pricing like a global CRO. Eurofins and Intertek will always beat you on breadth. Win on turnaround, scientist access and lot-by-lot data review. Quote 48-hour turnaround on a DAR assay and charge for it.
• Forecasting 80% utilisation in year one. Lab services take 4 to 9 months to land a first anchor customer through supplier qualification. Model 30% to 40% in year one.
• Ignoring the quality agreement. A customer's quality unit will send a 40-page questionnaire before the first sample. Budget a quality manager, even part time, before you sign anyone.
• Treating the method as portable. A HIC method optimised for one ADC rarely transfers to another. Charge for method development as a standalone line, not as a favour hidden in the assay price.

Technical Questions Buyers Ask Before They Hire You

A purchasing scientist will test your depth in the first call. These are the questions that come up most, with answers short enough to lift into your sales deck.

What is HIC used for?

Three main jobs. Analytically it measures DAR and drug-load distribution for cysteine-linked ADCs and separates oxidised or variant forms of monoclonal antibodies (Agilent application note). In purification it works as a polishing step after capture. In research it fractionates protein mixtures under mild conditions that preserve activity (GoldBio overview).

What salts and ligands does HIC use?

Ammonium sulfate is the standard binding salt, with sodium sulfate and sodium chloride as alternatives, and ammonium tartrate for MS-compatible work. Ligands run from weakly hydrophobic (ether, butyl) to strongly hydrophobic (phenyl, octyl). Pick a weaker ligand for a hydrophobic protein so it can be eluted without denaturation.

How does HIC differ from reversed-phase chromatography?

Reversed-phase uses organic solvents and acidic pH, which denature most proteins. HIC uses an aqueous salt gradient at near-neutral pH and keeps the molecule folded. That is why HIC is chosen for intact ADCs and RP is chosen when the molecule will be reduced into chains anyway.

Why can't I just run my ADC on ion exchange?

Conjugated payloads are small hydrophobic molecules that barely change a protein's charge but change its hydrophobicity a lot, so ion exchange cannot resolve the DAR species that HIC separates cleanly (PMC, AJICAP ADC purification study).

Our free business plan template and the case study library show how these technical answers fit into a go-to-market section.

Sample Business Plan Preview

The preview below uses a composite HIC lab in the Research Triangle with one bio-inert UHPLC, two analysts and a part-time quality manager. Every figure is derived from the assumptions on this page.

Year 1 combines 1,386 billed injections at $240 with six method-development projects, for about $417K of revenue against roughly $505K of costs, a first-year loss the funding ask is sized to absorb. Year 2 adds a third analyst, 2,400 injections and 14 projects. Year 3 assumes a second instrument and the first stability-study contract.

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your lab or product line at a glance, written to hold a lender's attention in 60 seconds
• Company Overview — Legal structure, ownership, site, and the scientific background of the founding team
• Industry Analysis — Market size, ADC and biosimilar pipeline demand, and the regulatory framework
• Customer Analysis — Biotech, CDMO and academic segments, their buying cycles and supplier-qualification steps
• Competitor Analysis — Contract testing groups, resin suppliers and in-house labs, with your point of difference
• Marketing Plan — Conference presence, technical application notes, and direct outreach to quality and CMC leads
• Operations Plan — Instrument schedule, sample-receipt workflow, QA review, and key milestones
• Management Team — Founder bios, scientific advisors, and the quality hire you plan to make

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements, with instrument utilisation as the main driver.

Frequently Asked Questions

Related Plans and Resources

Building adjacent to HIC? Our biopharmaceutical business plan template covers CDMO economics and phase-gated capital, and the business plan writer page explains how we work with technical founders.

• Facebook
• Instagram
• LinkedIn
• YouTube